Company Overview and News


Add VNRX
to your dashboard

Headline News

VolitionRX's (VNRX) CEO Cameron Reynolds on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good morning, ladies and gentlemen, and thank you for standing by, and welcome to VolitionRx Limited Third Quarter 2017 Earnings Conference Call. During today’s presentation, all parties will be on a listen-only mode. Following the presentation, the conference call will be opened for questions. [Operator Instructions] This conference is being recorded today, Friday, November 10, 2017.

VolitionRX Awarded $1.5 Million In Non-Dilutive Funding

2017-09-22 devicespace
ISNES, Belgium, Sept. 21, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded a loan and a non-repayable grant totaling $1.5 million from SOFINEX and the Walloon Region, Belgium. This is in addition to the $947,000 in loans previously provided by Namur Invest over the last 12 months, aggregating to approximately $2.45 million.

VolitionRX Announces The Initial Sale Of Its New Nu.Q Research Kits

2017-09-22 devicespace
ISNES, Belgium, Sept. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its strategy for a new range of Clinical Research Use Only (RUO) kits based on its proprietary Nucleosomics technology and the receipt of an order of RUO kits from a large multinational pharmaceutical company.

VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding

2017-09-21 prnewswire
ISNES, Belgium, Sept. 21, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded a loan and a non-repayable grant totaling $1.5 million from SOFINEX and the Walloon Region, Belgium. This is in addition to the $947,000 in loans previously provided by Namur Invest over the last 12 months, aggregating to approximately $2.45 million.

VolitionRX Announces Its European Colorectal Cancer Strategy

2017-09-20 devicespace
ISNES, Belgium, Sept. 19, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its colorectal cancer (CRC) strategy for Europe.  As part of its strategy, Volition plans to select a frontline panel to be validated in two large trials (4,300 and 10,000 sample), followed by CE marking, with a goal to launch a European frontline CRC screening product in 2018.

VolitionRx Announces its European Colorectal Cancer Strategy

2017-09-19 prnewswire
ISNES, Belgium, Sept. 19, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its colorectal cancer (CRC) strategy for Europe.  As part of its strategy, Volition plans to select a frontline panel to be validated in two large trials (4,300 and 10,000 sample), followed by CE marking, with a goal to launch a European frontline CRC screening product in 2018.

VolitionRX' (VNRX) CEO Cameron Reynolds on Q2 2017 Results - Earnings Call Transcript

2017-08-10 seekingalpha
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited’s Second Quarter 2017 Earnings Conference Call. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be opened for questions. [Operator Instructions] This conference is being recorded today, Thursday, August 10, 2017.

VolitionRX Schedules Second Quarter 2017 Earnings Conference Call And Business Update

2017-08-04 devicespace
ISNES, Belgium, Aug. 3, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) today announced it will host a conference call on Thursday, August 10, 2017 at 8:30 am Eastern time to discuss its financial and operating results for the second quarter of 2017, in conjunction with the filing of its quarterly report on Form 10-Q for the quarter ended June 30, 2017.

VolitionRX To Host A Conference Call Regarding A 13,500 Subject Colorectal Cancer Screening Trial With The Early Detection Research Network Of The U.S. NCI

2017-07-20 devicespace
AUSTIN, Texas, July 19, 2017 /PRNewswire/ -- VolitionRx Limited (Volition; NYSE MKT: VNRX), announced it will host a conference call tomorrow, July 20 at 8:30 AM U.S. Eastern Time to discuss its participation in a large multi-center clinical study with the Great Lakes New England Clinical Validation Center funded by the U.S. National Cancer Institute's (NCI) Early Detection Research Network (EDRN) in addition to providing a business update.

Volition America Announces A Colorectal Cancer Screening Trial Containing Approximately 13,500 Subjects In Collaboration With The Early Detection Research Network Of The U.S. NCI

2017-07-19 devicespace
AUSTIN, Texas, July 18, 2017 /PRNewswire/ -- Volition America, Inc. (Volition America), a wholly-owned subsidiary of VolitionRx Limited (Volition; NYSE MKT: VNRX), has signed an agreement to participate in a large multi-center clinical study with the Great Lakes New England Clinical Validation Center funded by the U.S. National Cancer Institute's (NCI) Early Detection Research Network (EDRN).

Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress

2017-06-30 prnewswire
ISNES, Belgium, June 30, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced it will be presenting at the EuropaColon Advocacy Masterclass and will be exhibiting at the European Society for Medical Oncology Congress on Gastrointestinal Cancer (ESMO GI).

VolitionRX Corrects An Earlier Announcement

2017-06-27 devicespace
ISNES, Belgium, June 27, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today has issued corrections to certain statements made in the press release issued by the Company on May 9, 2017 regarding the Company's Nu.Q Colorectal Cancer Screening Triage Test. Due to the Company's administrative error, Professor Hans Jorgen Nielsen from Hvidovre Hospital, University of Copenhagen, did not have adequate opportunity to review and comment upon the release or approve his included statement prior to its publication.

Final Results and Notice of AGM

2017-05-19 londonstockexchange
Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, announces its audited final results for the 12 months to 31 December 2016. The Group increased revenue in 2016 and has continued to reduce the cost of iodine production at the Group's IOsorb® plants despite challenges of falling iodine prices and brine supply due to regulations and diversion for fracking operations.

CUSIP: 928661107